ClinicalTrials.gg
CompletedNCT00212602Updated Jun 14, 2012

ONO-7436 Phase II Study in Japan

A Phase 2 interventional study of ONO-7436 in Malignant Tumor, sponsored by Ono Pharmaceutical Co. Ltd. Completed at 9 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2012-06-14.

Sponsored by Ono Pharmaceutical Co. Ltd · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
420
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

The purpose of this study is to examine the efficacy and safety of ONO-7436 for the prevention of cancer chemotherapy-induced nausea and vomiting in patients with malignant tumor

02

Conditions studied

  • Malignant Tumor

Keywords

  • ONO-7436, Aprepitant, Vomiting, Nausea
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 420 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Ono Pharmaceutical Co. Ltd is the lead sponsor of 63 studies on the registry; 2 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients age 20 years or older
  2. Patients with malignant tumor who are to be intravenously administered cisplatin as a single dose of 70 mg/m2 or more in under 3 hours
  3. Patients whose performance status is 0 to 2
  4. Other inclusion criteria as specified in the study protocol

Exclusion criteria

Exclusion Criteria:

  1. In case of patients who are previously treated with cisplatin, those having no past history of vomiting as of administration of cisplatin
  2. Patients who had vomiting or dry vomiting within 24 hours before the initial administration of the moderate or severe emetic chemotherapy (including cisplatin) on Day 1 of the study
  3. Pregnant women, nursing women, women of , women who wish to become pregnant or women using oral
  4. Other exclusion criteria as specified in the study protocol
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
420 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Patient proportion of complete response (no vomiting and no rescue treatment).

Secondary outcomes

  1. Proportion of patients with no vomiting, no rescue treatment, and no nausea (in each category or combination), frequency of vomiting, and time to first vomiting, and first rescue treatment.

07

Study locations

9 sites
  • Chubu Region Facility
    Chubu, Japan
  • Chugoku Region Facility
    Chugoku, Japan
  • Hokkaido Region Facility
    Hokkaido, Japan
  • Hokuriku Region Facility
    Hokuriku, Japan
  • Kanto Region Facility
    Kanto, Japan
  • Kinki Region Facility
    Kinki, Japan
  • Kyushu Region Facility
    Kyushu, Japan
  • Shikoku Region Facility
    Shikoku, Japan
  • Tohoku Region Facility
    Tohoku, Japan
08

References and documents

Publications

  • Takahashi T, Hoshi E, Takagi M, Katsumata N, Kawahara M, Eguchi K. Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin. Cancer Sci. 2010 Nov;101(11):2455-61. doi: 10.1111/j.1349-7006.2010.01689.x. PubMed 20718754 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 14, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00212602
Responsible party
Sponsor
First posted
Sep 21, 2005
Start date
Aug 2005
Last update
Jun 14, 2012

Study contacts

Project Leader, Development Planning
study director · Ono Pharmaceutical Co. Ltd
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aprepitant

Start the discussion